New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation

Abstract

Cytomegalovirus (CMV) viremia continues to be a frequent complication in the post haemopoietic stem cell transplant (HSCT) period despite a low incidence of CMV end-organ disease. A number of significant advances in the understanding and management of CMV infection have occurred in the last few years including improved diagnostics, monitoring of CMV immunity, availability of novel anti-CMV drugs, and emerging use of immunotherapies including CMV-specific T cell infusions. In addition to reviewing these advances we also explore some of the more practical prescribing issues of the older and newer CMV drugs including cost, toxicity and drug interactions to help clinicians navigate this new era ..